|
Market Closed -
OTC Markets
09:33:29 2026-06-03 EDT
|
5-day change | 1st Jan Change | ||
| 45.00 USD | +3.42% |
|
-13.43% | +12.50% |
| Market Cap | 61.67M 52.93M 49.68M 45.37M 85.63M 5.88B 86.04M 588M 228M 2.97B 232M 227M 9.83B | P/E 2024 |
225x | P/E 2025 | 8.64x |
|---|---|---|---|---|---|
| Enterprise Value | 69.28M 59.47M 55.81M 50.98M 96.21M 6.61B 96.67M 661M 256M 3.33B 260M 254M 11.04B | EV / Sales 2024 |
0.46x | EV / Sales 2025 | 0.24x |
| Free-Float |
17.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +3.42% | ||
| 1 week | -13.43% | ||
| Current month | -22.41% | ||
| 1 month | +7.12% | ||
| 6 months | -13.01% | ||
| Current year | +12.50% |
| 1 month | 45 | 51.98 | |
| Current year | 37 | 58 | |
| 1 year | 21 | 58 | |
| 3 years | 21 | 58 | |
| 5 years | 15.51 | 62 | |
| 10 years | 4.01 | 62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Darren Seirer
CEO | Chief Executive Officer | 52 | 2022-12-31 |
Nathan Shandy
DFI | Director of Finance/CFO | 39 | 2025-08-01 |
| Chief Executive Officer | 52 | 2014-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 2015-11-17 | |
John Gonzalez
BRD | Director/Board Member | 76 | 2016-05-31 |
Gregory Melsen
BRD | Director/Board Member | 74 | 2018-01-01 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/2/26 | Buy | Director | 225 | 0.0190% | ||
| 5/28/26 | Buy | Director | 900 | 0.0759% | ||
| 10/1/25 | Free | Director | 2,500 | 0.2107% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.42% | -13.43% | +12.50% | +50.00% | 61.67M | ||
| -2.25% | -3.10% | +38.65% | -1.87% | 83.24B | ||
| -5.77% | -14.18% | +505.18% | +33.71% | 63.41B | ||
| +0.35% | +3.93% | -19.58% | -35.42% | 59.49B | ||
| +0.76% | +3.53% | +0.08% | +36.18% | 52.94B | ||
| -1.38% | +1.47% | +10.64% | +170.57% | 49.86B | ||
| +0.14% | -0.22% | +61.70% | -16.40% | 32.62B | ||
| -1.23% | -0.27% | +52.52% | +100.63% | 26.29B | ||
| +9.69% | +11.76% | +14.67% | +224.85% | 22.23B | ||
| -1.15% | -0.30% | +60.29% | +121.68% | 17.22B | ||
| Average | +0.82% | +0.51% | +73.67% | +68.39% | 40.74B | |
| Weighted average by Cap. | -0.08% | -0.32% | +96.67% | +47.87% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 183M 157M 148M 135M 254M 17.47B 256M 1.75B 677M 8.81B 688M 673M 29.19B | 207M 178M 167M 153M 288M 19.79B 289M 1.98B 766M 9.98B 779M 762M 33.06B |
| Net income | 551K 473K 444K 405K 765K 52.55M 769K 5.25M 2.04M 26.51M 2.07M 2.02M 87.81M | 5.66M 4.86M 4.56M 4.16M 7.86M 540M 7.89M 53.93M 20.9M 272M 21.24M 20.78M 902M |
| Net Debt | 36.99M 31.75M 29.8M 27.22M 51.36M 3.53B 51.61M 353M 137M 1.78B 139M 136M 5.89B | 7.62M 6.54M 6.14M 5.6M 10.58M 726M 10.63M 72.61M 28.14M 366M 28.6M 27.98M 1.21B |
Employees
353
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- JANL Stock
Select your edition
All financial news and data tailored to specific country editions
















